A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features
A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features
复制标题
DOI：
10.1016/j.jocn.2017.10.002
复制
发表时间：
2018-01-01
影响因子：
2
通讯作者：
Hirose, Yuichi
中科院分区：
文献类型：
--
作者：
Moriya, Shigeta;Ohba, Shigeo;Hirose, Yuichi
脑干胶质瘤是不可能完全切除的，并且这种类型的胶质瘤患者的预后较差。因此，需要更有效的辅助治疗来延长生存期。贝伐单抗是一种内皮生长因子单克隆抗体，具有很强的抗血管作用，可以抑制肿瘤的进展。我们对6例脑干胶质瘤患者进行了回顾性研究，这些患者均显示恶性特征，经贝伐单抗治疗后，T2加权或液体衰减反转恢复磁共振成像评估，所有患者的肿瘤相关病变均减少，尽管贝伐单抗给药和预处理的开始时间不一致。4例患者的临床症状改善，2例患者的进展受到抑制。Karnofsky表现状态从平均56.7提高到71.7。肿瘤相关病变的中位缩小率为76.3%，但任何病例的肿瘤抑制均未持续。此外，5例患者死于肿瘤进展，1例患者死于坏死性结肠炎并发症。贝伐单抗给药后的中位无进展生存期为7个月。诊断后中位生存期为16.5个月，贝伐单抗可能是一种治疗进展性脑干胶质瘤的潜在选择。(C)2017爱思唯尔有限公司版权所有。
Brainstem glioma is impossible to resect completely, and patients with this type of glioma show a poor prognosis. Therefore, a more effective adjuvant therapy is required to prolong survival. Bevacizumab is an endothelial growth factor monoclonal antibody with strong anti-vascular effects, which may suppress tumor progression.We performed a retrospective study of data from 6 patients with brainstem glioma showing malignant features who were treated with bevacizumab.Tumor-associated lesions, as evaluated by T2 weighted or fluid-attenuated inversion-recovery magnetic resonance imaging, were reduced in all patients, although the timing of the start of bevacizumab administration and pretreatment were not uniform. Clinical symptoms improved in 4 patients and progression was inhibited in 2 patients. The Karnofsky performance status improved from 56.7 to 71.7 on average. The median reduction ratio of tumor-associated lesions was 76.3%, but tumor suppression did not last in any of the cases. Furthermore, 5 patients died of tumor progression, and 1 patient died of a complication of necrotizing colitis. The median progression-free survival after bevacizumab administration was 7 months. The median overall survival after diagnosis was 16.5 months.Bevacizumab might be a potential therapeutic option for progressive brainstem gliomas with malignant features. (C) 2017 Elsevier Ltd. All rights reserved.